Deletion of Tet2 in Mice Leads to Dysregulated Hematopoietic Stem Cells and Subsequent Development of Myeloid Malignancies

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2011 Aug 2

PMID 21803851

Citations 397

Authors

Zhe Li

Xiaoqiang Cai

Chen-Leng Cai

Jiapeng Wang

Wenyong Zhang

Bruce E Petersen

Feng-Chun Yang

Mingjiang Xu

Affiliations

Soon will be listed here.

Abstract

TET2 is mutated/deleted with high frequencies in multiple forms of myeloid malignancies including MDS, CMML, MPN, and AML. However, little is known regarding the biological function of TET2 and its role in the pathogenesis of myeloid malignancies. To study the function of TET2 in vivo, we generated a Tet2 knock out mouse model. Deletion of Tet2 in mice led to dramatic reduction in the 5-hydroxymethylcytosine levels and concomitant increase in the 5-methylcytosine levels in the genomic DNA of BM cells. The Tet2(-/-) mice contained an increased Lin(-)Sca-1(+)c-Kit(+) (LSK) cell pool before the development of myeloid malignancies. A competitive reconstitution assay revealed that Tet2(-/-) LSK cells had an increased hematopoietic repopulating capacity with an altered cell differentiation skewing toward monocytic/granulocytic lineages. Approximately 1/3 of Tet2(-/-) and 8% of Tet2(+/-) mice died within 1 year of age because of the development of myeloid malignancies resembling characteristics of CMML, MPD-like myeloid leukemia, and MDS. Furthermore, transplantation of Tet2(-/-), but not wild-type (WT) or Tet2(+/-) BM cells, led to increased WBC counts, monocytosis, and splenomegaly in WT recipient mice. These data indicate that Tet2-deficient mice recapitulate patients with myeloid malignancies, implying that Tet2 functions as a tumor suppressor to maintain hematopoietic cell homeostasis.

Citing Articles

Leukemogenic Kras mutation reprograms multipotent progenitors to facilitate its spread through the hematopoietic system.

Jang G, Park R, Esteva E, Hsu P, Feng J, Upadhaya S J Exp Med. 2025; 222(6).

PMID: 40072317 PMC: 11899982. DOI: 10.1084/jem.20240587.

TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.

Yang Y, Cathelin S, Liu A, Subedi A, Maher A, Hosseini M Nat Commun. 2025; 16(1):2384.

PMID: 40064887 PMC: 11894142. DOI: 10.1038/s41467-025-57614-y.

Deficiency of TET2-mediated KMT2D self-transcription confers a targetable vulnerability in hepatocellular carcinoma.

Jin Y, Rao K, Zheng J, Zhang X, Luo Y, He J PNAS Nexus. 2024; 3(11):pgae504.

PMID: 39564571 PMC: 11574621. DOI: 10.1093/pnasnexus/pgae504.

PROSER1 modulates DNA demethylation through dual mechanisms to prevent syndromic developmental malformations.

Fleming A, Knatko E, Li X, Zoch A, Heckhausen Z, Stransky S Genes Dev. 2024; 38(21-24):952-964.

PMID: 39562138 PMC: 11610933. DOI: 10.1101/gad.352176.124.

TET3 regulates terminal cell differentiation at the metabolic level.

Mulet I, Grueso-Cortina C, Cortes-Cano M, Gerovska D, Wu G, Iakab S Nat Commun. 2024; 15(1):9749.

PMID: 39557858 PMC: 11573987. DOI: 10.1038/s41467-024-54044-0.

References

Iyer L, Tahiliani M, Rao A, Aravind L . Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle. 2009; 8(11):1698-710. PMC: 2995806. DOI: 10.4161/cc.8.11.8580. View

Xing S, Wanting T, Zhao W, Ma J, Wang S, Xu X . Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008; 111(10):5109-17. PMC: 2384138. DOI: 10.1182/blood-2007-05-091579. View

Jankowska A, Szpurka H, Tiu R, Makishima H, Afable M, Huh J . Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009; 113(25):6403-10. PMC: 2710933. DOI: 10.1182/blood-2009-02-205690. View

Ko M, Huang Y, Jankowska A, Pape U, Tahiliani M, Bandukwala H . Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010; 468(7325):839-43. PMC: 3003755. DOI: 10.1038/nature09586. View

Tahiliani M, Koh K, Shen Y, Pastor W, Bandukwala H, Brudno Y . Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009; 324(5929):930-5. PMC: 2715015. DOI: 10.1126/science.1170116. View

Xu M, Tsuji K, Ueda T, Mukouyama Y, Hara T, Yang F . Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cell lines. Blood. 1998; 92(6):2032-40. View

Cai C, Zhou W, Yang L, Bu L, Qyang Y, Zhang X . T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development. 2005; 132(10):2475-87. PMC: 5576439. DOI: 10.1242/dev.01832. View

Andreu P, Colnot S, Godard C, Gad S, Chafey P, Niwa-Kawakita M . Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. Development. 2005; 132(6):1443-51. DOI: 10.1242/dev.01700. View

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M . Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144-7. PMC: 2710942. DOI: 10.1182/blood-2009-03-210039. View

10.

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

11.

Sage J, Miller A, Perez-Mancera P, Wysocki J, Jacks T . Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 2003; 424(6945):223-8. DOI: 10.1038/nature01764. View

12.

Tefferi A, Lim K, Abdel-Wahab O, Lasho T, Patel J, Patnaik M . Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009; 23(7):1343-5. PMC: 4654626. DOI: 10.1038/leu.2009.59. View

13.

Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N . TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009; 94(12):1676-81. PMC: 2791942. DOI: 10.3324/haematol.2009.011205. View

14.

Ito S, DAlessio A, Taranova O, Hong K, Sowers L, Zhang Y . Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010; 466(7310):1129-33. PMC: 3491567. DOI: 10.1038/nature09303. View

15.

Schaub F, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A . Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010; 115(10):2003-7. DOI: 10.1182/blood-2009-09-245381. View

16.

Haase V, Glickman J, Socolovsky M, Jaenisch R . Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A. 2001; 98(4):1583-8. PMC: 29300. DOI: 10.1073/pnas.98.4.1583. View

17.

Cai C, Martin J, Sun Y, Cui L, Wang L, Ouyang K . A myocardial lineage derives from Tbx18 epicardial cells. Nature. 2008; 454(7200):104-8. PMC: 5540369. DOI: 10.1038/nature06969. View

18.

Lorsbach R, Moore J, Mathew S, Raimondi S, Mukatira S, Downing J . TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003; 17(3):637-41. DOI: 10.1038/sj.leu.2402834. View

19.

Zhu Y, Romero M, Ghosh P, Ye Z, Charnay P, Rushing E . Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 2001; 15(7):859-76. PMC: 312666. DOI: 10.1101/gad.862101. View

20.

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View